You are here

Publications

Found 20 results
Sort by: Author Title [ Type (Asc)] Year
Filters: Author is Larsimont, D.  [Clear All Filters]
Conference Paper
Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S19.
Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G, Piccart MJ, et al. Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S30.
Equeter C, Ouriaghli EF, Haibe-Kains B, Stamatopoulos B, André F, Lallemand F, Filippov V, Larsimont D, Sotiriou C, Willard-Gallo K, et al. CD4+ T cells infiltrating breast tumors exhibit altered expression of T cell immune response genes in comparison with their counterparts from the lymph node and blood.
Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M, et al. Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures.
Sotiriou C, C.Equeter, Ouriaghli EF, Haibe-Kains B, Durbecq V, Larsimont D, Igniatiadis M, Desmedt C, Willard-Gallo K, Piccart MJ, et al. Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes. In: of Oncology JC ASCO Annual Meeting Proceedings. Vol. 20. ASCO Annual Meeting Proceedings. ; 2008. p. .
Desmedt C, Loi SM, Haibe-Kains B, Soree A, Lallemand F, Durbecq V, Larsimont D, Tutt A, Ellis P, Gillett C, et al. Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Desmedt C, Azambuja E, Di Leo A, Larsimont D, Durbecq V, Antoine D, Lallemand F, Haibe-Kains B, Cardoso F, Nogaret JM, et al. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients.
Durbecq V, Toussaint J, Haibe-Kains B, Desmedt C, Rouas G, Larsimont D, Buyse M, Bontempi G, Piccart MJ, Sotiriou C, et al. Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC).
Journal Article
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin Cancer Res [Internet]. 2008:5158-5165.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt A, Gillett C, Harris A, Bergh J, Foekens J, Klijn J, et al. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. Journal of Clinical Oncology. 2007.
Journe F, Durbecq V, Haibe-Kains B, Chaboteaux C, Rouas G, Laurent G, Larsimont D, Piccart MJ, Body JJ, Sotiriou C, et al. Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. European Journal of Cancer Supplements. 2008:112.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Journal of National Cancer Institute. 2006:262-272.
Haibe-Kains B, Desmedt C, Di Leo A, Azambuja E, Larsimont D, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, et al. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genomics Data. 2013.
Toussaint J, Sieuwerts A, Haibe-Kains B, Desmedt C, Rouas G, Harris A, Larsimont D, Piccart M, Foekens J, Durbecq V, et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009:424.
Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS ONE. 2010.
Toussaint J, Sieuwerts A, Durbecq V, Haibe-Kains B, Berns E, Harris AL, Larsimont D, Piccart M, Foekens J, Sotiriou C, et al. Molecular qRT-PCR grade index: a new tool for breast cancer (BC) patient grading improvement. European Journal of Cancer Supplements. 2008:140.
Desmedt C, A. DL, de Azambuja E, Larsimont D, B. H-K, J. S, Delaloge S, Duhem C, Kains JP, Carly B, et al. Multifactorial Approach to Predicting Resistance to Anthracyclines. Journal Clinical Oncology [Internet]. 2011.
Journe F, Durbecq V, Chaboteaux C, Rouas G, Haibe-Kains B, IdBoufker H, Laurent G, Sotiriou C, Larsimont D, Body JJ, et al. OC3. Farnesoid X receptor (FXR): A new marker for the prediction of bone metastases in breast cancer. Cancer treatment reviews [Internet]. 2008:50.
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans FW, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. PNAS. 2010.

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer